Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy
Name
PNAS-2010-Kolishetti-17939-44.pdf
Size
1.04 MB
Format
Adobe PDF
Checksum (MD5)
4efaee8cdb1c61c9a71f5915f75f1a49
Author(s)
Kolishetti, Nagesh
Dhar, Shanta
Valencia, Pedro Miguel
Lin, Lucy Q.
Karnik, Rohit
Lippard, Stephen J.
Langer, Robert
Farokhzad, Omid C.
Date Issued
October 2010
Journal
Proceedings of the National Academy of Sciences of the United States of America
Publisher
National Academy of Sciences (U.S.)
Citation
Kolishetti, N., S. Dhar, P. M. Valencia, et al. Engineering of Self-assembled Nanoparticle Platform for Precisely Controlled Combination Drug Therapy. Proceedings of the National Academy of Sciences 107(42): 17939–17944, 2010.
Version
Final published version
Abstract
The genomic revolution has identified therapeutic targets for a plethora of diseases, creating a need to develop robust technologies for combination drug therapy. In the present work, we describe a self-assembled polymeric nanoparticle (NP) platform to target and control precisely the codelivery of drugs with varying physicochemical properties to cancer cells. As proof of concept, we codelivered cisplatin and docetaxel (Dtxl) to prostate cancer cells with synergistic cytotoxicity. A polylactide (PLA) derivative with pendant hydroxyl groups was prepared and conjugated to a platinum(IV) [Pt(IV)] prodrug, c,t,c-[Pt(NH[subscript 3])[subscript 2](O[subscript 2]CCH[subscript 2]CH[subscript 2]COOH)(OH)Cl[subscript 2]] [PLA-Pt(IV)]. A blend of PLA-Pt(IV) functionalized polymer and carboxyl-terminated poly(d,l-lactic-co-glycolic acid)-block-poly(ethylene glycol) copolymer in the presence or absence of Dtxl, was converted, in microfluidic channels, to NPs with a diameter of ∼100 nm. This process resulted in excellent encapsulation efficiency (EE) and high loading of both hydrophilic platinum prodrug and hydrophobic Dtxl with reproducible EEs and loadings. The surface of the NPs was derivatized with the A10 aptamer, which binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells. These NPs undergo controlled release of both drugs over a period of 48–72 h. Targeted NPs were internalized by the PSMA-expressing LNCaP cells via endocytosis, and formation of cisplatin 1,2-d(GpG) intrastrand cross-links on nuclear DNA was verified. In vitro toxicities demonstrated superiority of the targeted dual-drug combination NPs over NPs with single drug or nontargeted NPs. This work reveals the potential of a single, programmable nanoparticle to blend and deliver a combination of drugs for cancer treatment.
MIT Department
MIT-Harvard Center for Cancer Nanotechnology Excellence
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Department of Chemistry
Massachusetts Institute of Technology. Department of Mechanical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1073/pnas.1011368107
